UBS Downgrades Shire Due to Risk from Clinical Trials

UBS analyst Guillaume van Renterghem downgraded Shire plc (NASDAQ: SHPG ) from Buy to Neutral due to downside risk from upcoming clinical trials. Renterghem commented that the Lifitegrast Phase III trial for dry eye and Vyvanse in Major Depression Disorder could have "disappointing results" due to poor selection of